Skip to main content

Advertisement

Table 2 Demographics of primary dogs in a clinical field study investigating the safety and efficacy of Simparica Trio™

From: Safety and efficacy of a novel oral chewable combination tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against natural flea infestations in client-owned dogs in the USA

CategoryTreatment group
Simparica Trio™
(n = 167)
Afoxolaner
(n = 84)
Total
(n = 251)
No. of females (%)78 (46.7)41 (48.8)119 (47.4)
No. of males (%)89 (53.3)43 (51.2)132 (52.6)
No. neutered (%)99 (59.3)60 (71.4)159 (63.3)
No. not neutered (%)68 (40.7)24 (28.6)92 (36.7)
Mean initial age in years (range)5.1 (0.2–17.0)4.9 (0.2–14.0)5.0 (0.2–17.0)
Pure-bred/mixed breed %50.3/49.748.8/50.249.8/50.2
No. short hair length (%)91 (54.5)50 (59.5)141 (56.2)
No. medium hair length (%)56 (33.5)27 (32.1)83 (33.1)
No. long hair length (%)20 (12.0)7 (8.3)27 (10.8)
No. indoors and outdoors (%)65 (38.9)39 (46.4)104 (41.4)
No. mostly indoors (%)90 (53.9)43 (51.2)133 (53.0)
No. mostly outdoors (%)12 (7.2)2 (2.4)14 (5.6)